3 QUESTIONS ON . . . ‘Spillover’ Savings for the Oncology… : Oncology Times
An abstract is unavailable.
Related Articles
Psilocybin May Help Alleviate Cancer-Related Depressive Symptoms
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
A national estimate of mental disorders and mortality outcomes in cancer survivors
The prevalence of various mental disorders and their impact on mortality among cancer survivors were assessed. The results revealed that mental disorders significantly increased the…
Greater Certainty of Survival Valued Over Speedier Drug Access
The FDA’s accelerated approval pathway allows for quicker access to drugs based on surrogate endpoints, such as progression-free survival. However, when considering new cancer drugs,…
Cervical cancer prevention and control in women living with human immunodeficiency virus
Despite being highly preventable, cervical cancer is the fourth most common cancer and cause of cancer death in women globally. In low-income countries, cervical cancer…
Why doesn’t MD Anderson accept Affordable Care Act insurance plans?
MD Anderson does not accept health insurance plans through the Affordable Care Act due…
Heart disease linked to elevated risk for advanced breast cancer
Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have pre-existing cardiovascular disease, according to results of a…
Association Between Migraine and Open Angle Glaucoma: A… : Journal of Glaucoma
Previous studies have reported that migraine headaches may be one of the possible risk factors for open angle glaucoma (OAG); however, a consensus has not…
BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC
BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.
Newly Diagnosed mHSPC: Androgen Receptor Pathway Inhibitor Selection
Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate cancer (mHSPC) involves considering factors such as disease burden, patient…
